63 related articles for article (PubMed ID: 9280823)
1. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement.
Ciana G; Cuttini M; Bembi B
N Engl J Med; 1997 Sep; 337(10):712. PubMed ID: 9280823
[No Abstract] [Full Text] [Related]
2. Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate).
Ostlere L; Warner T; Meunier PJ; Hulme P; Hesp R; Watts RW; Reeve J
Q J Med; 1991 Jun; 79(290):503-15. PubMed ID: 1946931
[TBL] [Abstract][Full Text] [Related]
3. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate.
Harinck HI; Bijvoet OL; van der Meer JW; Jones B; Onvlee GJ
Lancet; 1984 Sep; 2(8401):513. PubMed ID: 6147561
[No Abstract] [Full Text] [Related]
4. Case 20-2003: Gaucher's disease.
Beutler E
N Engl J Med; 2004 Jan; 350(4):416-7; discussion 416-7. PubMed ID: 14736939
[No Abstract] [Full Text] [Related]
5. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.
Samuel R; Katz K; Papapoulos SE; Yosipovitch Z; Zaizov R; Liberman UA
Pediatrics; 1994 Sep; 94(3):385-9. PubMed ID: 8065868
[TBL] [Abstract][Full Text] [Related]
6. Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3.
Bembi B; Agosti E; Boehm P; Nassimbeni G; Zanatta M; Vidoni L
Acta Paediatr; 1994 Jan; 83(1):122-4. PubMed ID: 8193463
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of bone marrow failure in Gaucher's disease with low-dose modified glucocerebrosidase.
Mistry PK; Davies S; Corfield A; Dixon AK; Cox TM
Q J Med; 1992 Jul; 83(303):541-6. PubMed ID: 1484931
[TBL] [Abstract][Full Text] [Related]
8. Uveitis in Gaucher disease.
Dweck A; Rozenman J; Ronen S; Zimran A; Elstein D
Am J Ophthalmol; 2005 Jul; 140(1):146-7. PubMed ID: 16038664
[TBL] [Abstract][Full Text] [Related]
9. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
10. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
[TBL] [Abstract][Full Text] [Related]
11. Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health.
Mastaglia SR; Watman NP; Oliveri B
Osteoporos Int; 2010 Nov; 21(11):1959-62. PubMed ID: 20535608
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
Howe W; Davis E; Valentine J
Dev Neurorehabil; 2010 Feb; 13(1):31-6. PubMed ID: 20067343
[TBL] [Abstract][Full Text] [Related]
13. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial.
Wilkinson JM; Eagleton AC; Stockley I; Peel NF; Hamer AJ; Eastell R
J Orthop Res; 2005 Jan; 23(1):1-8. PubMed ID: 15607868
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and therapy of Gaucher disease].
Ehlen C; Heintges T; Niederau C
Med Klin (Munich); 1995 May; 90(5):284-90. PubMed ID: 7791695
[TBL] [Abstract][Full Text] [Related]
15. Fibromyalgia and Gaucher's disease.
Brautbar A; Elstein D; Pines B; Krienen N; Hemmer J; Buskila D; Zimran A
QJM; 2006 Feb; 99(2):103-7. PubMed ID: 16293672
[TBL] [Abstract][Full Text] [Related]
16. [Gaucher disease with multiple bone necrosis treated by enzyme replacement therapy and pamidronate].
Abe M; Minoguchi M; Jinbo J; Kikuchi Y; Chiba A; Shibata Y; Kogo Y
Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2421-3. PubMed ID: 15624481
[No Abstract] [Full Text] [Related]
17. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
18. Renal involvement in adult Gaucher's disease after splenectomy.
Chander PN; Nurse HM; Pirani CL
Arch Pathol Lab Med; 1979 Aug; 103(9):440-5. PubMed ID: 582376
[TBL] [Abstract][Full Text] [Related]
19. Alternative indications for bisphosphonate therapy.
Landesberg R; Eisig S; Fennoy I; Siris E
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):27-34. PubMed ID: 19371812
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease.
Drugan C; Jebeleanu G; Grigorescu-Sido P; Caillaud C; Craciun AM
Blood Cells Mol Dis; 2002; 28(1):13-20. PubMed ID: 11814307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
